Monopar Therapeutics (MNPR) reported a Q2 net loss Wednesday of $0.62 per diluted share, compared with a loss of $0.35 a year earlier.
Analysts surveyed by FactSet expected a loss of $0.66.
The company did not report any revenue for the quarter.
As of June 30, the company said it has $134.3 million in cash, cash equivalent and investments. It added that it expects its current funds to support operations through at least Dec. 31, 2027.
Price: 115.00, Change: +0.54, Percent Change: +0.47
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments